MarketBeatFEB 233 min read$INMD

InMode (NASDAQ:INMD) Shares Gap Down - Here's Why

InMode (NASDAQ:INMD) shares gapped down following a prior closing price of $15.22, opening at $14.11, and last trading around $14.01. The company's recent earnings reported $0.46 EPS, beating consensus estimates, but revenue slightly missed expectations. Despite a consensus "Hold" rating from analysts with an average target price of $16.80, the stock has seen varied analyst adjustments, including a recent price target cut by UBS Group.

Original reporting

MarketBeat · MarketBeat

Published Feb 23, 2026, 7:18 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Feb 23, 2026, 7:30 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Source · MarketBeat

Decision brief

The 30-second read

$INMDBearishMed

Why it matters

The gap down suggests profit-taking or reassessment by investors despite solid earnings, possibly influenced by analyst rating adjustments.

Market read

The news is highly relevant for traders holding or considering trading INMD, especially in the short term.

What to watch

Potential for sector-wide recovery or positive news in upcoming weeks that could offset current negative sentiment.

Timing: Immediate to short-term (next 1-2 weeks)

Background

InMode reported quarterly earnings with EPS beating estimates but revenue slightly missing expectations, leading to mixed investor reactions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INMDBearishMedium confidence

Context

The news directly pertains to InMode (NASDAQ:INMD), highlighting recent stock price movements, earnings report, and analyst ratings.

Expected impact

Short-term decline of approximately 5-10% expected; potential stabilization or rebound may occur within 1-2 weeks.

Evidence & confidence

The gap down following earnings beat indicates a possible overreaction or profit-taking, but fundamentals remain solid. Technical support levels around $14.00 could serve as a bounce point.

Market effects

Sector

The medical device and life sciences sector may experience short-term volatility; investors should monitor sector ETFs for broader impact.

Regional

Limited regional impact; primarily affecting US-based investors and markets.

Global

Minimal; company-specific news with limited global implications.

Counterpoint

What could challenge this read

The stock may have overreacted to short-term factors; positive earnings beat and solid fundamentals could lead to a recovery.

Key entities

Company
InMode Ltd.
A medical technology company specializing in minimally invasive aesthetic and medical treatment solutions.

Read at source ← All news

AUG 5

$INMDMedAI 8/10

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.

prnewswire.com6 min

AUG 5

$INMDMed

InMode Ltd. (INMD): Financial results for Q2 2026

InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno

SEC EDGAR 6-K2 min

JUL 10

$INMDMed

InMode Confirms Receipt of Unsolicited Proposal

InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.

prnewswire.com1 min

JUL 9

$INMDMedAI 9/10

InMode Shares Jump After Steel Partners Tables Higher Takeover Proposal (INMD)

InMode Ltd (INMD) shares rose about 4% premarket after Steel Partners Holdings proposed to buy the medical aesthetics company for $16.75 per share in cash, a 20% premium to $13.95 and above a prior $16.20 bid by CEO Moshe Mizrahy. Steel Partners urged an independent committee, questioned governance and possible MNPI around share purchases, and cited 2026 adj. EBITDA of $65M vs guidance $73M-$78M.

yahoo.com4 min

JUL 9

$INMDHighAI 9/10

InMode stock surges on Steel Partners’ $16.75 buyout offer By Investing.com

InMode Ltd (NASDAQ:INMD) shares rose about 4% premarket after Steel Partners Holdings offered to buy the company for $16.75 per share in cash. Steel Partners, a major shareholder, cited a 20% premium to $13.95 and said it would allow rollover of up to 40% of equity into Steel-owned InMode. It urged an independent committee, challenged CEO Moshe Mizrahy, and referenced 2026 adjusted EBITDA of $65 million versus guidance of $73 million to $78 million.

investing.com4 min

SEP 8

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min